Studies to establish quality control ranges for SB-265805 (LB20304) when using national committee for clinical laboratory standards antimicrobial susceptibility test methods [5]

Journal of Clinical Microbiology

Volumn 37, Issue 1, 1999, Pages 279-280

  Erwin, Meredith E ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; DIFFUSION; DILUTION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032924072     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.1.279-280.1999     Document Type: Letter

References (6)

1. Cormican, M. G., and R. N. Jones. 1997. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41:204-211.
2. National Committee for Clinical Laboratory Standards. 1994. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
3. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests, 6th ed. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
4. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
5. National Committee for Clinical Laboratory Standards. 1998. Development of in vitro susceptibility testing criteria and quality control parameters. Tentative guideline M23-T3. National Committee for Clinical Laboratory Standards, Wayne, Pa.
6. Oh, J.-I., K.-S. Pack, M.-Y. Ahn, M.-J. Kim, C. Y. Hong, I.-C. Kim, and J.-H. Kwak. 1996. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 40:1564-1568.